
X4 Pharmaceuticals Inc
NASDAQ:XFOR

Intrinsic Value
The intrinsic value of one
XFOR
stock under the Base Case scenario is
100.67
USD.
Compared to the current market price of 3.4 USD,
X4 Pharmaceuticals Inc
is
Undervalued by 97%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Fundamental Analysis


Revenue & Expenses Breakdown
X4 Pharmaceuticals Inc
Balance Sheet Decomposition
X4 Pharmaceuticals Inc
Current Assets | 95.7m |
Cash & Short-Term Investments | 87m |
Receivables | 1.2m |
Other Current Assets | 7.6m |
Non-Current Assets | 34.3m |
PP&E | 4.1m |
Intangibles | 27.2m |
Other Non-Current Assets | 3m |
Free Cash Flow Analysis
X4 Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
X4 Pharmaceuticals Inc
Revenue
|
31.4m
USD
|
Cost of Revenue
|
-5.5m
USD
|
Gross Profit
|
25.9m
USD
|
Operating Expenses
|
-34.4m
USD
|
Operating Income
|
-8.6m
USD
|
Other Expenses
|
23.2m
USD
|
Net Income
|
14.6m
USD
|
XFOR Profitability Score
Profitability Due Diligence
X4 Pharmaceuticals Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.

Score
X4 Pharmaceuticals Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
XFOR Solvency Score
Solvency Due Diligence
X4 Pharmaceuticals Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Score
X4 Pharmaceuticals Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XFOR Price Targets Summary
X4 Pharmaceuticals Inc
Dividends
Current shareholder yield for XFOR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?